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THE ROLE OF THE CACNA1A GENE IN THE PATHOGENESIS OF 
EPISODIC ATAXIA 2 AND SPINOCEREBELLAR ATAXIA 6
FREDRIC FABIANO
ABSTRACT
CACNA1A encodes for the voltage-gated calcium channel CaV2.1.
Mutations to CACNA1A are known to cause an assortment of disorders,
including episodic ataxia 2, spinocerebellar ataxia 6, familial hemiplegic migraine
1, and more. The pathogenic nature behind these mutations is still unknown, but
recent studies have given new information that points toward certain
conclusions. In particular, episodic ataxia 2 appears to be caused (in some
mutations) by misfolding and improper trafficking of both wild-type and mutant
CaV2.1 channels. Spinocerebellar ataxia 6 is more complicated, as recent findings
of the bicistronic nature of CACNA1A may mean that the disorder is more akin
to a polyglutamine disease than a channelopathy. The goal of this thesis is to
review the literature available that addresses these disorders and their
progression, as well as future treatment strategies.
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INTRODUCTION
CACNA1A is the gene that encodes the α1 subunit of the P/Q-type
calcium ion channel CaV2.1 in humans. CaV2.1 is a voltage-gated channel, with
the α1 subunit creating its pore. Auxiliary subunits α2δ and β regulate calcium
influx as well as provide functional diversity. It is a presynaptic channel which
mediates neurotransmi er release via neuronal excitation (Ishikawa et al., 2005).
Mutations to the CACNA1A gene are known to cause numerous neurological
disorders, such as episodic ataxia type 2 (EA2), spinocerebellar ataxia type 6
(SCA6), familial hemiplegic migraine type 1 (FHM1), cognitive impairment,
epilepsy, and more. This paper intends to examine the cause, effects, and
treatments of EA2 and SCA6 due to CACNA1A mutations.
Location and Splicing of CaV2.1
CaV2.1 is a presynaptic channel located in mammalian brain and spinal
cord neurons. Channel expression is especially high within the cerebellum
(Westenbrook et al., 1995). Areas of the brain related to migraines, such as the
cerebral cortex and the trigeminal ganglia all express CaV2.1. It has been shown
to be present in brain stem nuclei of the periaqueductal grey region, dorsal
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raphe, and the raphe magnus, all of which are related to nociceptive central
control (Hillman et al., 1991).
One of the most important areas of CaV2.1 expression when discussing
ataxias is its prominent expression in cerebellar Purkinje cells. Purkinje cells have
a pacemaker frequency of around 40 Hz (Tejwani and Lim, 2020). They are
modulated directly by excitatory synapses of parallel fibers and climbing fibers,
as well as by local inhibitory neurons. Parallel fibers project from cerebellar
granule neurons, and climbing fibers project from the inferior olivary nucleus.
Because Purkinje cells are the only source of output for the cerebellar cortex, their
proper function is essential for fine movement and coordination. Mutations to
CaV2.1 and other ion channels located in Purkinje cells lead to irregular
pacemaker firing from Purkinje cells, and are a significant area of research when
examining the pathophysiology of ataxias.
In the many areas where CaV2.1 expression occurs, different isoforms are
created via alternative splicing of the CACNA1A gene. Splice variants have been
shown to have differing subcellular locations and electrophysiological properties
(Bourinet et al., 1999). The function of these variants can differ so starkly that
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they have opposite effects on the voltage necessary for steady-state inactivation.
Figure 1 shows the effects on the voltage dependence of inactivation in channels
with differing polyglutamine lengths due to splice variation with and without an
asparagine-proline (NP) chain in domain IV. With respect to a 13 polyglutamine
control, longer polyglutamine α1 subunits had an increased Ca2+ influx when
asparagine-proline was present, and a decreased Ca2+ influx when
asparagine-proline was absent (Toru et al., 2000).
CaV2.1 expression can achieve even greater variety through the auxiliary
subunits α2δ and β. Differing β subunits have shown to have an effect on rates of
inactivation, steady-state inactivation, and the occurrence of “slow” and “fast”
gating modes (Luvise o et al., 2004).
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FIGURE 1. α1A with 13, 24, and 28 polyglutamines, with and without an
asparagine-proline stretch (+NP, -NP), co-expressed with α2δ and β1a subunits in
HEK293 cells. In this experiment the 13 polyglutamine α1A is the control, as expanded
polyglutamine stretches are a cause of SCA6. A conditioning prepulse of varying
intensity (-120 mV to 40 mV) was applied for 10s, before the test pulse (20-30 mV) for
50 ms.
These graphs show the a comparison of voltage dependence of inactivation for Ca2+
via whole-cell patch clamp technique. While α1A(-NP) with 24 and 28 polyglutamines
showed a respective decrease of 6 and 11 mV in their voltage dependence of
inactivation, α1A(+NP) with 28 polyglutamines showed an increase of 5 mV compared
to their 13 polyglutamine forms.
(Toru et al., 2000)
4
Relation of CaV2.1 to Other Calcium Channels
As a presynaptic voltage-gated channel, CaV2.1 contributes to release of
neurotransmi ers in response to action potentials. It is activated by a strong
depolarization, and is blocked by the polypeptide toxin ω-Agatoxin IVA
(ω-AgaIVA). While other Ca2+ channels also play a role in neurotransmission,
such as CaV2.2 (N-type) and CaV2.3 (R-type), CaV2.1 (P/Q-type) has the most
dominant function of the three (Pietrebon, 2005). There was a previous
hypothesis that this was due to a limited number of spots in the membrane for
interaction between Ca2+ channels and exocytotic machinery, and CaV2.1
preferentially couples with the machinery over the other channels. There is
evidence that this changes with age, as CaV2.1 expression is comparable low
postnatally and increases dramatically within the following days to months
(Iwasaki et al., 2000). In addition, in CaV2.1 knockout mice there was an increased
reliance on CaV2.2 (N-type) channels for neurotransmission, potentially
providing evidence for the limited ‘slots’ of Ca2+ channels. Recent studies in the
Calyx of Held synapse, however, provided evidence against the limited slots
theory by showing that overexpression of CaV2.1 increased currents, indicating
that membrane calcium channels are unlikely to be saturated (Lubbert et al.,
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2019). The increased reliance on CaV2.2 is more likely caused by upregulation of
channel expression when intracellular calcium increases are insufficient. Despite
this, channel function is not fully returned in these mice, likely because of the less
efficient coupling of the N-type channel (Ishikawa et al., 2005).
A feature that differentiates CaV2.1 from other pre-synaptic Ca2+ channels
is its ability to be modulated Ca2+-binding proteins. Neuronal calcium sensors
interact with the intracellular C-terminus of CaV2.1, modulating its function. By
removing the calmodulin-binding domains of these Ca2+-sensor proteins, it was
shown that CaV2.1 is both activated and inactivated in a Ca2+-dependent manner
(Mochida, 2008). This is thought to have an effect on synaptic plasticity and aid
in information-processing.
Role of CaV2.1
CaV2.1 has been shown to have important functions in many parts of the
brain, with particularly high expression in the cerebral cortex. The majority of
pyramidal neurons require CaV2.1 for excitatory synaptic transmission, with the
channel also having an effect on some inhibitory transmission. The channel
initiates excitatory neurotransmi er release from granule cell axons and climbing
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fibers to Purkinje cells. It also initiates inhibitory synaptic neurotransmission
between Purkinje cells (Min  et al., 1995).
In addition to the above effects, CaV2.1 is also selectively coupled with
calcium-activated potassium channels (KCa) in cerebellar Purkinje cells (Womack
et al., 2004). These cells fire spontaneously, even in the absence of synaptic
transmission, with KCa channels controlling the firing rate and
afterhyperpolarization. These potassium channels are only activated by CaV2.1
channels, even when CaV2.3 channels or high extracellular calcium
concentrations are present. By blocking CaV2.1 channels, the effect of blocking
KCa channels is also seen. This leads to frequent and irregular firing of Purkinje
cells. Because of how Purkinje cells and CaV2.1 relate to ataxias, it is thought that
the regulation of intrinsic, spontaneous firing may be involved in the
pathogenesis of CaV2.1 disorders.
In a study on thalamocortical function, CaV2.1 was shown to be necessary
for the generation of γ-band oscillations associated with consciousness (Llinás et
al., 2007). Mice lacking CaV2.1 channels showed an absence of γ-band activity in
electroencephalograms, despite partial synaptic transmission being rescued by
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the N-type calcium channel CaV2.2. Further blockage of T-type calcium channel
CaV2.3, using the toxin SNX-482, caused the mice to enter a coma-like state. This
effect was not seen in the control mice with functional CaV2.1 channels. The
abnormalities caused by a lack of CaV2.1 have a great effect on the
thalamocortical system, and thus on the system’s role in motor and cognitive
control.
In the trigeminovascular system, CaV2.1 channels play a major role in the
release of neurotransmi ers from nociceptors in the meninges. As a result, much
research has been done on the pathophysiology of familial hemiplegic migraine
type-1 in relation to CaV2.1. When studying a mutation of CaV2.1 that decreased
the expression of channels by half, heterozygous CaV2.1-/+ mice showed a reduced
response to induced neuropathic pain and inflammatory pain (Luvise o et al.,
2006). This is despite no changes in motor ability or cognitive function. CaV2.1-/-
mice similarly showed a reduced response to neuropathic and inflammatory
pain, but also an increased sensitivity to acute noxious non-injurious thermal
stimuli. This study shows that CaV2.1 channels hold a role in both antinociceptive
and pronociceptive responses when interacting with different stimuli.
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α1ACT Expression
In the past few years, it has been discovered that CACNA1A expresses
bicistronic mRNA. The α1 subunit of CaV2.1 is expressed by the first cistron,
while a transcription factor α1ACT is expressed by the second cistron. This
transcription factor has been found to drive gene expression in cerebellar
Purkinje cells and is necessary for neonatal survival, though adult expression is
seemingly unnecessary (Du et al., 2019). While comparatively li le is known
about α1ACT, studies so far indicate that it has a prominent role in the
pathogenesis of SCA6.
Episodic Ataxias
Episodic ataxias are uncommon neurological disorders (incidence of less
than 1/100,000), often associated with other calcium and potassium
channel-related disorders such as hemiplegic migraines, dystonia, epilepsy, and
more. The symptoms of episodic ataxias depend on the type, but include periods
of loss of coordination, nystagmus, epilepsy, and tinnitus. They originate from
the cerebellum, the part of the brain that controls fine motor skills and balance.
While episodic ataxia type 1 is associated with mutations in the gene KCNA1
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and the KV1.1 potassium channel, episodic ataxia type 2 is associated with
mutations in the gene CACNA1A and the CaV2.1 calcium channel.
There are more than 70 known mutations of the CACNA1A gene that
cause episodic ataxia 2 (EA2), with most of them being deletions, insertions, or
nonsense mutations (Jen et al., 2007). These mutations lead to truncated or
otherwise non-functioning protein expression through intron inclusion or exon
exclusion. The disorder is autosomal dominant in inheritance.
EA2 is the most common episodic ataxia, and its symptoms generally
develop during early childhood to teenage years. A acks can last for hours,
usually include nystagmus, rarely causes epilepsy, and never causes tinnitus.
Those suffering from a acks show a loss of balance and slurred speech. More
than half of patients also suffer from migraines, vertigo, and nausea. They may
also suffer from progressive ataxia and fluctuating weakness.
Spinocerebellar Ataxias
Spinocerebellar ataxias have some similar ataxic symptoms to EA2, but
vary in terms of cause and onset.
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Spinocerebellar ataxias have been separated into two subfamilies based on
their modes of inheritance. Spinocerebellar ataxia, autosomal recessive disorders
(SCARs) are those inherited in an autosomal recessive manner. Spinocerebellar
ataxias (SCAs) are inherited in an autosomal dominant manner. Forms of
X-linked and mitochondrial inheritance ataxia disorders have also been
discovered. However, even with these subfamilies spinocerebellar ataxia
disorders vary wildly in their causes.
Just among SCAs there are over 40 different known disorders, with a
diverse amount of mutations among them. The mutations occur in very different
genes across the body. The most common mutation is missense, with sixteen
known disorders originating from that. Other examples are trinucleotide repeats
(SCA36), chromosomal deletions (SCA20, SCA39), and 5’ UTR CAG repeat
expansions (SCA12) (Tejwani and Lim, 2020). Of particular interest are CAG
repeats, called polyglutamine or polyQ expansion mutations. PolyQ expansions
have been in seven independent genes as the cause of seven different SCAs:
SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, and dentatorubral-pallidoluysian
atrophy (DRPLA). Not all of these genes encode ion channels, but all of the
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mutations result in cerebellar degeneration. Because they all cause similar
symptoms, the belief is that all of these genes are involved in Purkinje cell
excitability and/or transcriptional regulation.
PolyQ expansion mutations of CACNA1A are known to cause SCA6.
Unlike EA2, SCA6 is late onset (mean age of around 45 years) and ataxic
symptoms progress slowly. The repeats in CACNA1A are pure CAG repeats,
with zero interruption of the (CAG)n tract being noted in a UK cohort of 173
(Wiethoff et al., 2018). The polyQ expansion is located by the C-terminal end of
specific isoforms of CaV2.1 expressed in cerebellar Purkinje cells (Zhuchenko et
al., 1997). Patients with SCA6 show major loss of Purkinje cells and cerebellar
degeneration. Compared to other polyQ expansion disorders, SCA6 can occur at
a relative low number of CAG repeats, with the age of onset decreasing as the
number of repeats increases. Zhuchenko et al. showed that a family with 27
repeats had an age of onset of 28-31 years for every member, while other families
with 22-23 repeats had an age of onset of 40-50 years.
12
PATHOGENESIS & HEREDITY OF EA2 AND SCA6
Episodic Ataxia 2
To understand the pathophysiology behind EA2, it is important to
understand how CaV2.1 function is affected by the CACNA1A mutations. While
most of these mutations result in truncated proteins via a disrupted reading
frame, some of them do not. By observing the missense mutations rather than the
nonsense, insertion, and deletion mutations, it is possible to see how differing
levels of CaV2.1 channel dysfunction affect EA2 progression and symptoms.
Studies conducted on CaV2.1 channels with mutations that caused EA2
showed that a particular mutation caused partial channel function. The observed
effects were an increase in positive voltage dependence of activation, increased
rate of deactivation, and an overall reduction in current density (Wappl et al.,
2002). Analysis of the channel’s open probability and availability showed no
change in channel availability, but a possible decrease in open probability. Mean
open times were also significantly reduced. This study shows that not all EA2
mutations result in non-functional α1A subunits. A further point of interest here
is whether this effect differs when compared to other CACNA1A mutations and
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CaV2.1 channel splices. It is noted that CACNA1A mutations that cause FHM1
show the opposite effect: reduced voltage dependence of activation, and
increased Ca2+ current. In addition, the aforementioned study was performed
using Xenopus oocytes, and there is evidence that the effects of EA2 mutations
differ when expressed in mammalian cells and when used for different splice
variations.
A major question to answer is whether the autosomal-dominant nature of
these mutations comes from haploinsufficiency, dominant-negative effects, or
both. When EA2 mutants (including missense and nonsense mutations) were
co-expressed in HEK293T cells with wild-type CaV2.1 channels,
dominant-negative effects were observed to be improper folding and trafficking
of the WT channels (Jeng et al., 2008). The wild-type CaV2.1 channels were
stained with green fluorescent protein (GFP). When expressed alone, they
showed proper trafficking with the majority of the protein being localized on the
cell membrane. However, when expressed alongside EA2 mutant CaV2.1
channels, the majority of wild-type channels was localized in the endoplasmic
reticulum (ER). These findings are shown in Figures 2 and 3. Patch-clamp
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techniques showed that Ca2+ current was dramatically reduced, indicating loss of
function.
Interestingly, when these cells were incubated at low temperature (27°C)
whole-cell patch clamp showed a return of function. This indicates that EA2
mutations cause misfolding of CaV2.1 channels which results in signaling for
proteasomal degradation via trafficking to the ER. However, these studies were
done in HEK293T cells, and it is still unknown whether the dominant-negative
effect on trafficking is present in neurons. CaV2.1 channels have splice variations,
and it is possible that specific variants may respond differently to EA2 mutant
channel expression. In particular, it has been shown that while CaV2.1 channels
with long C-terminus ends show significant dominant-negative effects from EA2
mutants, CaV2.1 channels with short C-terminus ends show no such effect unless
the molar ratio of wild-type : mutant is 1:10 (Jeng et al., 2006). Because the splice
variants vary based on age and location, more research focusing on CaV2.1
channels in cerebellar neurons is necessary to fully understand whether EA2
pathology is due to a dominant-negative effect on folding and trafficking.
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FIGURE 2. (A) The location of
the six EA2 mutations of interest.
An ‘X’ indicates a premature stop
codon. These were all imaged in
HEK293T cells.
(B) GFP-tagged wild-type CaV2.1
channels and CAA366, a
fluorescent antibody against
human α1A subunit.
(C) FM4-64 is a plasma
membrane marker, confirming
membrane localization.
(D) WGA is wheat germ
agglutinin, another plasma
membrane marker.
(E) Differing localization pa erns
of GFP-tagged wild-type,
showing membrane dominant,
cyto-membrane, and
cytoplasm-dominant
respectively.
(Jeng et al., 2008)
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FIGURE 3. Imaging done with
HEK293T cells. CaV2.1 mutations are
those shown in Figure 2.
Anti-GM-130 is a golgi marker,
ER-Tracker and DsRed-ER are two
ER markers. EA2 mutant CaV2.1
channels are shown to shift
localization from the plasma
membrane to the ER.
(Jeng et al., 2008)
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Another consideration for a potential pathway for EA2 pathology is based
on the idea of limited membrane CaV2.1 channel ‘slots.’ Because there may be a
limited number of spaces for calcium channels to occupy, the introduction of
aberrant or dysfunctional mutant channels would decrease the amount of fully
functioning CaV2.1 channels in use. This was shown to occur with CACNA1A
mutations that cause familial hemiplegic migraine type 1 (Cao et al., 2004). If this
were to also occur with EA2 mutant channels, if would provide another possible
reason behind the autosomal dominant heredity.
Spinocerebellar Ataxia 6
A similar point of discussion in the pathophysiology of spinocerebellar
ataxia type 6 is whether the disorder comes about from a toxic gain-of-function
mechanism or via a change in function of CaV2.1 channels. The toxic
gain-of-function is one seen in other polyQ mutations that results from a buildup
of the aberrant protein. However, as seen in Figure 1, the exact cause and effect
of SCA6 pathology can change depending on a number of different factors.
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As shown in Figure 1, splice variants can alter the effects of the same
SCA6 mutation quite dramatically. The initial takeaway from these results is that
SCA6 mutations result in a change of function for CaV2.1 channels. However,
another study also tested the CaV2.1 channels with 13 and 28 polyglutamine
repeats in different cell types, and the results showed conflicting results.
The study was done using CaV2.1 channels without an asparagine-proline
chain in domain IV. In mouse Purkinje cells, there was no change in the voltage
of activation for CaV2.1 channels, regardless of whether the channel had 13 or 28
polyglutamine repeats (Saegusa et al., 2007). This lack of change in the voltage of
activation cannot be explained through a change in channel density, as
expression levels of CaV2.1 mRNA were found to be the same as in the control.
The interpretation of this data is that the loss of Purkinje cells, believed to be the
pathogenesis of SCA6, is not caused by a change in CaV2.1 channel function.
Further studies show that the age of onset and severity of symptoms is
dependent on the length of the polyQ repeats (Watase et al., 2008). Three CaV2.1
channels with repeat lengths of 14Q (normal human SCA6 allele), 30Q (expanded
allele), and 84Q (hyperextended allele) were expressed in mice. Mice with shorter
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repeats had a later age of onset than those with longer repeats. In addition to age
of onset, it also altered the ratio of splice variants present in the cells. As the
amount of CAG repeats in the CACNA1A were increased, the amount of long
C-terminus (MPI) isoforms increased compared to the amount of short
C-terminus (MPc) isoforms. It is currently unclear why this change in splicing
occurs, but it is possible that the CAG repeats may affect the binding of specific
proteins to the motifs, changing the splicing. This indicates that SCA6 mutations
may also be responsible for a change in function of CaV2.1 channels through a
decrease in specific isoforms. In addition, the current density was decreased in
the SCA6 models, though it is unclear what the exact reason for this is. There is
evidence that this is caused by a decrease in available surface CaV2.1 channels, as
shown in Figure 4. Unexpectedly, this decrease in current was the same
regardless of polyQ repeat length, indicating that this effect occurs independent
of the amount of CAG repeats. Also, regardless of the length of polyQ repeats,
the voltage dependence of activation and inactivation did not significantly differ
from the control.
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FIGURE 4. CaV2.1 expression in SCA6 mutant Purkinje neurons, featuring a
polyQ repeat of Q84. (A) Images of Purkinje neurons with stains for type
III-tubulin and CaV2.1. (B) Quantification of fluorescent imaging. Cells with
SCA6 mutation have a marked decrease in CaV2.1 fluorescence.
(Watase et al., 2008)
Previous studies have shown that CaV2.1 channels with polyQ repeat
expansion sequences go through a cleavage of their C-terminal region (Kubodera
et al., 2003). These cleaved C-terminal fragments were translocated to nucleus
and caused a toxic effect in the cell.  These fragments accumulate in the cell over
time. Similar cleavage also happens in cells overexpressing CaV2.1 channels. The
fragments from these cells are just as toxic as the polyQ variant, but the cells do
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not show aggregation of these fragments and do not ordinarily undergo cell
death. The belief here is that the polyQ repeats provide a degree of resistance to
proteolysis that wild-type fragments do not have. In this way, the polyQ
expansion isn’t in itself toxic, but indirectly causes a toxic effect.
Similarly, C-terminal cleavage occurs in L-type CaV1.2 Ca2+ channels
(Gomez-Ospina et al., 2006) . The fragments are also translocated to the nucleus,
where they act as a transcription factor that regulates CaV1.2 expression of a
variety of genes. At this time, the function of CaV2.1’s C-terminal fragments has
not been widely studied despite the known importance of C-terminal length
regarding disorder progression. Recent studies have shown that alternative
splicing of CaV2.1’s C-terminal region plays a major role in preventing
neurological disorders in mice (Aikawa et al., 2017). They show that the
cytoplasmic C-terminal is not necessary for basic protein function, but that it
interacts with other proteins that help against disease arising. In addition, the
recent finding of α1ACT brings into question what parts of previous studies were
actually referring to the α1ACT transcription factor, rather than a cleavage
fragment. More research should be done on how the length of the C-terminal tail
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affects the function and toxicity of cleaved fragments that naturally occur, and
whether they are truly important considering α1ACT.
Watase et al. also showed that, similar to other polyQ disorders, SCA6
mutations caused an aggregation of insoluble protein in the cytoplasm of the
Purkinje cells. The aggregation occurred in an allele dosage- and age-dependent
manner, providing further evidence that SCA6 pathogenesis is rooted in toxic
gain-of-function. Interestingly, they did not find aggregation of the toxic, cleaved
CaV2.1 C-terminal regionals in these cells. It is possible that the smaller fragments
were hidden among the larger protein aggregates, but it also points to the
possibility that the cleavage product is not necessary for the SCA6 pathology
these mice showcased.
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RECENT LITERATURE
Bicistronic Nature of CACNA1A mRNA
CACNA1A is one of the rare genes in humans that has been shown to
express bicistronic mRNA (Du et al., 2013). The first cistron expresses the α1
subunit of CaV2.1. The second cistron encodes for a transcription factor named
α1ACT. This transcription factor affects the expression of genes involved in the
development of Purkinje cells and other neural cells. The bicistronic nature of the
mRNA is conferred through internal ribosomal entry sites (IRES), which allow
ribosome binding to sequences within the mRNA. Because this transcription
factor is formed from the 3’ end of the mRNA, in cases of SCA6 mutations the
α1ACT includes the polyQ repeat expansion.
The α1ACT transcription factor increases expression of certain Purkinje
cell genes, enhances neurite outgrowth, and has been show to partially restore
wild-type phenotype to CACNA1A knockouts. In particular, target genes that
have been shown to have enhanced expression in the presence of α1ACT include
B cell translation gene 1 (BCTG1) and progranulin. In SCA6 mutations, however,
this enhanced expression was lost.
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CACNA1A knockout mice develop severe symptoms of ataxia, seizures,
and muscle spasms shortly after birth, and typically die within the first three
weeks. When these mice expressed α1ACT alone, even without α1 subunit
expression, wild-type phenotype was restored and lifespan returned to normal.
With SCA6 α1ACT mutations, motor functions still persisted but to a far lesser
extent than those with WT.
To test the effect α1ACT has on Purkinje cell development, α1 -/-knockout
mice were bred to have Purkinje cell specific α1ACT. This was done using a
Purkinje cell specific promotor, Pcp2. These mice had improved mental and
motor function, but not a complete return to normal. They gained more weight
and lived a week longer than the knockout mice lacking Purkinje cell α1ACT. The
hypothesis is that this is due to increased synaptic and dendritic development.
For several genes, mRNA levels that are normally decreased in knockout mice
showed a 1.5 to 3 times increase when Purkinje cell specific α1ACT was present.
These findings indicate that CACNA1A plays a major role in proper
morphological and functional development of Purkinje cells. No mice with
Purkinje cell α1ACTSCA6 were present, indicating unviabilility.
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Episodic Ataxia 2 Knockin Mice Models
More recent studies have started a empting to create EA2 knockin mice
models in order to be er characterize the dominant inheritance mechanism of
the disorder. In the first model, a missense mutation of c.4486T>G (p.F1406C)
was added to the mouse CACNA1A gene (Rose et al., 2014). Interestingly, mice
homozygous for this mutation do not show outward motor dysfunction, but do
show a loss-of-function in Purkinje cells via about a 70% reduction in CaV2.1
current density. Heterozygous mice had a normal motor phenotype, with a
possible slight decrease in current density. This is in contrast to humans with a
single EA2 allele, which does cause ataxias. Mice hemizygous for the mutation
did, however, exhibit a motor disorder phenotype. The phenotype’s severity was
somewhere between +/- mice and -/- mice, indicating that the EA2 allele has
partial function that still results in motor dysfunction.
To test for a possible gain-in-function or effect on transcription, levels of
CaV2.1 α1 subunits in mouse cerebellum and frontal cortex were tested in +/+,
EA2/+, and EA2/EA2 mice. Western blot showed that all three genotypes had
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similar levels of protein expression. Therefore, this mutation was shown to not
affect protein transcription or translation.
The mice cerebellum were also checked for any histopathological signs.
No abnormalities were seen, and there were no signs of abnormal Purkinje cell
death. This indicates that the missense mutation used does not cause significant
cerebellar degeneration in mice.
Explanations for why even homozygous EA2 mutants did not show a
motor phenotype, despite the reduction in current density, include the specific
location of the mutation and possible compensation from other calcium ion
channels. Location is important as CACNA1A encodes both the α1 subunit of
CaV2.1 and the α1ACT transcription factor. Because the transcription factor plays
an important role Purkinje cell development, a missense mutation in a different
location of the gene can have vastly different effects. In addition, the study
showed that Purkinje cells exhibited partial compensation for the reduction in
current density through CaV1.2 and CaV2.2 channels normally present in the cells.
27
One of the most interesting discoveries from this mouse model is the
implications regarding pathogenesis solely in Purkinje or granule cells. To test
the cell types separately, they isolated the hemizygous EA2/- genotype to the cell
type of interest while expressing EA2/+ genotype in every other cell. While mice
with one EA2 allele and one knockout allele were shown to have a motor
impairment, heterozygous EA2/+ mice with a single wild-type allele did not.
Thus, by expressing a hemizygous genotype in one cell type and a heterozygous
genotype in the other, they can test the effect of the mutation in each cell type
alone. They did this using floxing to create EA2/flox genotype mice. L7-Cre
transgene expresses Cre recombinase in postnatal Purkinje cells, excising the
loxP sites from the flox allele to create a knockout heterozygote in Purkinje cells
only. To test granule cells, they used Math1-Cre transgene to express Cre
recombinase only in granule cells.
The results can be seen in Figure 5. There were no significant differences
in motor function from the control in either experiment. What is interesting
about these results is how the effect in Purkinje cells differs from the expected
result of motor dysfunction when EA2 is hemizygously expressed. Previous
studies indicated that expression of ataxic mutations of CACNA1A in Purkinje
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cells alone was sufficient to cause episodic dystonia and ataxia (Raike et al.,
2012). Considering that neither cell type alone caused significant motor
dysfunction, the likely explanation is that this mutation requires both aberrant
Purkinje cells and granule cells to produce an ataxic phenotype.
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FIGURE 5. Rotarod performance of mice with cell-specific EA2 mutations.
(A) PC-specific EA2/- mice showed no significant changes in motor ability
compared to control mice.
(B) Granule cell-specific EA2/- mice also showed no significant changes in
motor ability compared to control mice
(Rose et al., 2014)
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Another mouse model was generated some time later with the EA2
causing R1497X nonsense mutation in CaV2.1 (Dorgans et al., 2017). This
mutation was one that was previously found in a human family line (Jen et al.,
1999). These mice were more in line with human phenotypes, with heterozygous
showing clear muscle weakness, ataxia, and epilepsy, but otherwise normal
growth and lifespan. Homozygous mice died postnatally within three weeks.
The heterozygous CaV2.1+/R1497X mice showed no signs of Purkinje cell
degeneration or cerebellar cell death. This indicates that unlike some other
ataxias, the phenotype does not arise due to loss of Purkinje or granule cells.
Purkinje cell development was also shown to be unaffected, though their
dendritic spines were less numerous and of an irregular shape.
The rate of spontaneous Purkinje cell spiking was reduced in CaV2.1+/R1497X
mice compared to wild-type, indicating an area of neuronal dysfunction. This
change in Purkinje cell firing also has an effect on granule cell develop, as
granule cells synapse with the Purkinje cells via their axonal parallel fibers. Thus,
these results have to be viewed as coming about from dysfunction of both
Purkinje cells and granule cells.
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The most overtly significant difference in CaV2.1+/R1497X mice was the
change in CaV2.1 expression levels. At 18 days old, CaV2.1 levels were decreased
by 77%. In adult mice, CaV2.1 levels were decreased by 65%. Expression of other
ion channels, including CaV2.2 and CaV1.2, were unchanged. The drop in CaV2.1
levels is unlikely to be caused by haploinsufficiency alone, providing more
evidence toward a toxic gain-of-function effect. However, the low level of
cerebellar CaV2.1 also indicates that there is no accumulation of misfolded CaV2.1
protein in the cells. This suggests that the theory that accumulation of unfolded
protein is a cause of the abnormal CaV2.1 levels and affected trafficking does not
apply to this animal model.
To test whether these changes in CaV2.1 channel levels are due to
abnormal trafficking, they examined lipid rafts that the channel is inserted into
after leaving the endoplasmic reticulum. With wild-type mice, CaV2.1 channels
were shown to be present in the lipid rafts of mice cerebella. CaV2.1+/R1497X mice,
on the other hand, showed a stark decrease in CaV2.1 channels in the lipid rafts to
<10% of wild-type levels. The amount of lipid rafts present, as well as auxiliary
subunit α2δ2 associated with trafficking of CaV2.1 to the lipid rafts, were all
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normal. Also interesting is that localization of another channel, potassium
channel SK2, to lipid rafts was also decreased in CaV2.1+/R1497X mice, as shown in
Figure 6. Reduction in SK2 activation is correlated with abnormal Purkinje cell
firing, so a reduction in SK2 trafficking may contribute to the decrease in Purkine
cell firing seen in these mice (Hosy et al., 2011). Potential causes for this change
in SK2 trafficking include a possible interaction between the two channels once
CaV2.1 leaves the ER. This data provides in vivo evidence of the dominant
negative effect of EA2 mutations on trafficking for both wild-type and truncated
proteins.
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FIGURE 6. Quantified densiometric measurements of CaV2.1+/R1497X (+/R) and
wild-type (+/+) mice cerebella. Flotilin is a lipid raft marker. α2δ2 is an isoform
of the α2δ auxiliary subunit that is especially important for targeting of CaV2.1
to lipid rafts. SK2 is a Ca2+ activated potassium channel.
(Dorgans et al., 2017)
SCA6’s Relationship to α1ACT
The second cistron of CACNA1A mRNA encodes for α1ACT, a
transcription factor, and is located in the same region as known SCA6 mutations.
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Therefore, mutations of SCA6 cause the polyQ repeat expansions to be included
in the expressed α1ACT. When expressed in culture, these altered α1ACT no
longer have the ability to act as a transcription factor, hindering cell
development, and have a toxic effect that results in cell death (Du et al., 2013).
When expressed in transgenic mice, cerebellar atrophy and symptoms of ataxia
occur.
With the discovery of α1ACT, polyQ repeat SCA6 mutations of the
transcription factor were compared against wild-type. While wild-type increases
expression of multiple different genes, SCA6 mutant α1ACT had no such increase
in the genes observed. α1ACTWT rescued CACNA1A knockout mice from ataxic
symptoms and low lifespan, but while α1ACTSCA6 mice had a much less severe
reduction of motor dysfunction they still exhibited ataxic symptoms. Knockout
mice who were bred to express α1ACT solely in Purkinje cells regained some
motor function, but α1ACTSCA6 mice were absent, suggesting unviability.
PC12 cells expressing α1ACTSCA6 experienced around two times the
amount of cell death compared to vector control cells. PC12 cells expressing
α1ACTWT show no increase in cell death compared to the vector control cells. In
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other cell cultures, such as HEK and primary granule cells, α1ACTSCA6 featuring
the ployQ repeat expansion was also shown to cause cell death in cells with fully
function α1A channel subunits (Du and Gomez, 2018). The fact that this occurs
even when CaV2.1 channel function is not directly altered suggests that
α1ACTSCA6 gains a toxic effect from the polyQ repeat expansion. This provides an
explanation for why some cells expressing α1ACTSCA6 show reduced viability.
Mice overexpressing α1ACTSCA6 were also tested for symptoms of SCA6
over two years. While overt ataxia and changes in lifespan were not present,
changes in gait were noticed especially as the mice aged. The molecular layer of
the cerebellum showed a decrease in thickness for α1ACTSCA6 mice, though there
were no severe cell losses of the cerebellum after two years. As SCA6 is a
late-onset disorder, it is possible that cerebellar cell death and symptoms of
ataxia increase over time. Because the most striking feature of SCA6 is severe loss
of Purkinje cells, more studies need to be done to fully elucidate the effects of
α1ACTSCA6 over longer periods of time.
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TREATMENT FOR EA2 AND SCA6
EA2 - Acetazolamide
The earliest discovered treatment for EA2 was acetazolamide, also known
as Diamox. Its effectiveness was revealed serendipitously (Griggs and Nu ,
1995). A patient was believed to be suffering from periodic paralysis and given
acetazolamide, and found that the drug treated all of her symptoms. Years later,
it was noticed that her nystagmus and ataxia were indicative of episodic ataxia 2.
The drug was found to be effective at treating EA2 in many other patients, and is
still being used to this day.
How acetazolamide treats EA2 is still unknown. Notably, patients with
EA2 have an increased cerebellar pH level that is remedied by acetazolamide. It
has more common uses treating symptoms of epilepsy, periodic paralysis,
glaucoma, altitude sickness, and more. It is a carbonic anhydrase inhibitor,
causing a metabolic acidosis effect. This also causes it to have diuretic properties
that allows use for treatment of edema (Aslam and Gupta, 2021). By lowering
bicarbonate levels, brain lactate and pyruvate decrease and brain pH drops.
37
More research into how pH affects the pathology of EA2 could prove useful in
more fully understanding the disorder’s progression.
It is possible that the abnormally high cerebellar pH levels in EA2 patients
have a causal effects on the a acks of ataxia. A change in pH affects
transmembrane conductance, with an increase in pH enhancing potassium
conductance (Strupp et al., 2007). EA2 a acks are increased when the patient
undergoes stress and exercise; both events may lead to hyperventilation and an
increase in intracellular pH. This resultant change in potassium conductance also
affects other ion channels such as CaV2.1. In particular, EA2 patients have been
shown to have altered voltage dependence of activation, part of which may be a
result of the difference in pH.
Despite its use, there have been no completed randomized, placebo-controlled
trials on the effectiveness of acetazolamide. In addition, side effects including
fatigue, hyperhydrosis, nephrolithiasis (kidney stones), and more have been
reported. Other carbonic anhydrase inhibitors, such as Sulthiame, have been
found to cause fewer side effects with similar results in EA2 treatment, but they
are still considered as an alternative to acetazolamide.
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EA2 - 4-Aminopyridine
A more recent discovery for EA2 treatment is 4-aminopyridine, a
voltage-gated potassium channel blocker. The drug was found to be efficient in
preventing EA2 a acks even in some patients that did not respond to
acetazolamide. By blocking potassium channels, 4-aminopyridine increases the
excitability of Purkinje cells and helps regulate EA2 Purkinje cell’s irregular
firing (Kalla et al., 2016). It is a nonselective potassium channel blocker, but it
especially blocks KV1.5 voltage-activated potassium channels. This delays
repolarization of the cells, increasing the duration of the action potentials (Kalla
and Strupp, 2019). Increasing the activity of Purkinje cells also increases the rate
of inhibitory GABA release, whose effects on other cerebellar neurons may also
affect the pathogenesis of EA2.
4-aminopyridine has gone through a randomized, double-blind, crossover
trial with 10 subjects with episodic ataxias, and results showed that those given
4-aminopyridine had a significant reduction in a ack frequency (Strupp et al.,
2011).
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EA2 - Future Treatments
Because the disfunction of CaV2.1 has an effect on calcium-dependent
potassium channels, KCa channels have also been considered as therapeutic
targets. An example of this is the use of chlorzoxazone, an FDA approved muscle
relaxant. Chlorzoxazone selectively activates KCa channels, and a study was done
on its effectiveness for treating EA2 mice (Alviña and Khodakhah, 2010). In in
vitro Purkinje cells from cerebellar slices, it was shown that chlorzoxazone
significantly restored pacemaking activity. In vivo, mice given the drug had a
dramatic increase in motor function that decreased over time after
administration of the treatment ceased. Additionally, the frequency of a acks
also decreased, although no mice had a complete cessation of a acks. More
studies need to be done, but based on these findings it is possible that potassium
channel activators/inactivators could be a potential treatment option for
CACNA1A mutation disorders.
Recent research has also been done to examine how patients who do not
respond well to acetazolamide can still receive treatment. Those with certain
variants of EA2 mutations are known to have a poor or transient recovery
response on acetazolamide, with only roughly 50-70% responding well. One
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patient who had a 50% reduction in a ack frequency still had a acks weekly,
and was given the antiepileptic drug levetiracetam in addition to acetazolamide
(Lee et al., 2017). The use of antiepileptic drugs to treat EA2 has not been
properly studied. However, the patient saw a large improvement in a ack
frequency and severity, with milder a acks happening roughly once a month.
Levetiracetam as a treatment for EA2 has not been thoroughly studied, so
the mechanisms behind its use together with acetazolamide is still unknown.
Levetiracetam is known to inhibit pre-synaptic calcium channels by binding to
synaptic vesicle glycoprotein SV2A. This is another area of interest that could
help shed light on the pathogenesis of EA2.
SCA6 - Current Treatments
SCA6 is a rare, late-onset disorder that largely does not affect life span.
Therapeutics for it are lacking. Symptoms such as vertigo and muscle weakness
can be mildly alleviated through medication, canes, and wheelchairs.
Acetazolamide has also been shown to help with ataxic symptoms of SCA6,
though less so after taking it for a year (Yabe et al., 2003). There is also evidence
that 4-aminopyridine may also help with ataxic symptoms in SCA1, SCA3, and
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SCA6 (Giordano et al., 2013). Future therapeutic strategies are currently being
tested as more is known about the pathologic effects of the polyQ repeat
expansion.
SCA6 - RNA Targeting
SCA6 is one of many polyQ expansion disorders, including other
spinocerebellar ataxias and Huntington’s disease. Thus, there has been a
substantial amount of research into treatments that may also work for SCA6.
Recent promising strategies in mice involve RNA-targeting therapies, including
the use of antisense oligonucleotides (ASOs) (Keiser et al., 2015). The strategy is
that ASOs will reduce the amount of pathogenic polyQ proteins through gene
suppression.
ASOs are single-stranded nucleotides that alter expression of a specific
protein via binding to RNA complimentary to their base sequence. They are
generally 12-22 bases in length. After binding, ASOs recruit RNAse H which
degrades the specified RNA. They can also simply block interaction with the
targeted RNA, preventing translation or altering splicing (Cerritelli and Crouch,
2008). The function of the ASO changes based on its structure and its location of
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binding. ASOs cannot cross the blood brain barrier, but they are soluble in
artificial cerebrospinal fluid. Thus, delivery can be achieved through direct
injection into the cerebrospinal fluid around the brain and spinal cord.
When used to study Huntington’s disease, mice injected with ASOs
targeting human huntingtin expression showed a reduction of more than 75% of
human huntingtin mRNA (Kordasiewicz et al., 2012). The decrease in mRNA
persisted for three months after treatment was stopped, as ASOs have a
relatively long half-life.
ASOs have also been tested for the treatment of SCA3, another
neurodegenerative polyQ disorder affecting the deubiquitinating enzyme
ataxin-3. The ASOs used were able to significantly reduce the amount of
pathogenic ataxin-3 in both mice expressing human ataxin-3 and in human
fibroblasts (Moore et al., 2017). In three of the five ASOs tested, treatment
resulted in an ataxin-3 reduction of more than 50%. The ASOs tested were
non-allele-specific, as ataxin-3 is likely not an essential protein.
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Whether ASOs can be used to treat SCA6 has not be tested yet, but it is a
promising topic for future research. Recent SCA6 research indicates that the
disorder should possibly be looked at as more similar to a polyQ protein
disorder, rather than as a channelopathy. In particular, the effect of the polyQ
repeat in α1ACT is a very interesting area for future therapeutics. Allele-specific
ASOs, that allow for expression of non-polyQ CaV2.1, has potential as a treatment
for SCA6 with more study.
SCA6 - IRES Targeting
Another, more recent, angle of approach has been to target the IRES
region of CACNA1A that is responsible for the expression of α1ACT. In doing so,
expression of CaV2.1 should be unaffected, while expression of α1ACT should be
markedly reduced. A study done in HEK cells showed that miRNA and small
molecule targeting of the CACNA1A IRES were able to effectively reduce α1ACT
levels while not decreasing the levels of full length CaV2.1 (Pastor et al., 2018).
The small molecules found to inhibit the CACNA1A IRES were found by
screening FDA-approved drugs for those which block IRES activity. The four
drugs found that allowed for expression of CaV2.1 while reducing the levels of
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α1ACT were ajmaline, nocodazole, chlorambucil, and deferoxamine. How these
particular drugs inhibit the ribosomal entry site is unknown at this time, but
when be er understood may one day allow for creation of a more efficient
therapy.
In vivo studies of miRNA effectiveness on SCA6 symptoms were done
using mice infected with an adeno-associated virus to express α1ACT with
differing polyQ repeats. α1ACTQ11 mice behaved as control mice did, while
α1ACTQ33 mice developed motor dysfunction. When treated with miRNA
targeting the CACNA1A IRES, α1ACTQ11 mice had no change while α1ACTQ33
mice showed a stop in the development of impaired mobility. This suggests that
targeting of the IRES, and therefore inhibiting α1ACT expression, may be an
effective therapeutic strategy for SCA6. Possibilities for this treatment also
include the small molecules listed above, as well as ASOs designed to target the
CACNA1A IRES.
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CONCLUSION
CaV2.1 has been shown to be an important protein that is essential for
cerebellar function. There is still much to be learned about the channel and its
variations, with findings having significant clinical implications. As more is
understood about the channel, opportunities to learn about and treat CACNA1A
disorders are becoming more and more apparent.
Episodic ataxia type 2 is a complicated disorder, with the many different
types of mutations resulting in differing outcomes. What can be said about
nonsense mutations, as shown by both in vivo and in vitro studies, is that the
likely cause of pathology is due to misfolding and improper trafficking of CaV2.1.
This affects both the EA2 allele and the wild-type. Whether this is the pathway in
all EA2 mutations is unknown, but a large amount of evidence points to this
being one the of the main effects in many EA2 patients. Further studying of the
effects on pH from EA2 mutations, and how KCa activators/inactivators affect
CACNA1A mutations, may help increase understanding of how treatment of
EA2 can be improved.
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Spinocerebellar ataxia type 6 should likely not be looked at as a
channelopathy, but instead be approached as a polyQ repeat expansion disorder.
It is unclear whether channel function is directly affected, but with the discovery
of α1ACT it seems most likely that much of SCA6’s pathogenesis is a result of
changes to this transcription factor. While current treatments are lacking, there is
a promising chance that treatments used for other polyQ disorders, as well as
those targeting IRESs, may also help those suffering from this disorder.
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